In this study, have demonstrated the expression
of CB2 and TRPV1 in human and rodent skeletal
muscle as potential receptor sites for the previously
observed effects of AEA [19]. Drugs targeting CB1, CB2,
FAAH and TRPV1 for the treatment of obesity, pain
and inflammation are currently under development
[26,42–44]. The expression of CB2, FAAH and TRPV1
along with CB1 in human and rodent skeletal muscle istherefore an important consideration in the development of
these therapeutic targets. Endocannabinoids may have a
complex role in skeletal muscle biology.